Sector News

Astex reveals partnership with MSD

August 13, 2023
Life sciences

Astex Pharmaceuticals, a company focused on the development of novel small molecule therapeutics for oncology and diseases of the central nervous system, has announced a global collaboration with MSD.

The aim of the partnership is to establish small molecule candidates with activity towards a tumour suppressor protein for treating cancer.

Astex, under the terms of the agreement, will incorporate its fragment-based drug discovery platform to develop compounds targeting multiple forms of the ‘p53’ tumour suppressor protein, while also providing MSD with lead compounds for further optimisation and preclinical development.

Meanwhile, MSD is granted an exclusive international license to study, develop and commercialise candidates arising from the collaboration.

Harren Jhoti, president and chief executive officer at Astex, was encouraged by the partnership: “Astex is applying its fragment-based drug discovery capability to design and generate small molecule modulators tailored to a wide range of potentially important therapeutic targets. This new alliance builds on our existing productive collaboration and allows us to combine our expertise and assets with MSD’s wide-ranging oncology capabilities.”

George Addona, senior vice president, discovery and translational medicine at MSD, added: “At MSD we are committed to driving innovation with the goal of improving outcomes for patients with cancer. We look forward to building on our collaboration with the Astex team to advance this potentially impactful area of oncology research.”

Astex will receive an upfront payment of $35m and is also eligible for milestone payments linked with the achievement of preclinical, clinical, regulatory and sales milestones. These will come to around $500m per program, as well as tiered royalties on sales of products emerging from the partnership.

Ultimately, MSD will assume responsibility for funding all future research and development of candidates, in addition to the commercialisation of products globally.

by John Pinching

Source: pharmatimes.com

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach